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Abstract
Background: This multicenter study describes the type-specific prevalence of HPV infection in the general
population from central and southern Italy, comparing the data with previously published Italian studies.
Methods: Women aged from 25 to 65 who attended cervical cancer screening in five different Italian regions were
tested for HPV infection with Hybrid Capture II (HCII) low and high risk probes. Women repeating Pap-test upon
unsatisfactory or positive results, or as a post-treatment and post-colposcopy follow-up analysis, were excluded
from our study. High risk (HR) HPV positive samples were typed using GP5+/GP6+ primed PCR, followed by
Reverse Line Blot for 18 high/intermediate risk HPV types, while low risk (LR) HPV positive samples were tested
with type specific primers for HPV6 and HPV11.
Results: 3817 women had a valid HCII test: 350 of them (9.2%) were positive for HR probes, 160 (4.2%) for LR
probes, while 57 women were positive for both. Multiple infections were detected in 97 HR HPV positive women.
The most common types were HPV 16 (3%), 31 (1.2%), 51 (1%). HPV6 ranked fifth (0.6%), HPV18 ranked tenth (0.5%)
and HPV11 sixteenth (0.3%).
In Sardinia the prevalence of high-risk infection was 13%, significantly higher than the mean value (p < 0.00005).
The distribution of the most frequent types did not significantly differ by centre (p = 0.187) and age (p = 0.085).
Conclusions: Because cervical cancer incidence and Pap test coverage is lower in southern than in northern Italy,
a lower prevalence of high-risk infections in the general population was expected in the south. However,
prevalence detected in this study for the south of the country is slightly but significantly higher than the rest of
Italy. The consequence may be an epidemic of cervical cancer in the next decades if adequate screening programs
are not implemented there.
Background
The identification of HPV as a necessary cause of
cervical cancer [1] has been rapidly followed by the
introduction of new tools for prevention: HPV test and
vaccine.
In Italy the vaccine has been recommended, free and
offered to 11-year old girls since the beginning of
2008 [2].
Pre-vaccination campaign studies
In 2006, the Italian Centre for Disease Control and
Prevention planned a set of studies to assess HPV epide-
miology before introducing the vaccine. The main aims
of these studies were: to describe the prevalence of types
in the healthy population and in women affected by cer-
vical neoplasia, to monitor any type replacement in vacci-
nated cohorts, to assess the proportion of infections by
HPV strains present in the vaccine, to estimate the cost
effectiveness of various vaccine and screening strategies,
and to describe the knowledgea b o u tt h ev i r u sa n da t t i -
tudes towards HPV vaccination in young women.
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population was performed in three different studies,
focusing on the following populations:
￿ the NTCC (New Technologies in Cervical Cancer)
biobank, which included all HPV positive samples
from about 50.000 women aged between 25 and 60
in central and northern Italy, excluding Rome [3-5].
They were tested for HR HPV types;
￿ a large sample of women aged between 18 and 26,
newly recruited across Italy (sample size: 4000
women). They underwent HPV test and typing;
￿ a large sample of women aged between 25 and 65,
newly recruited in Rome and southern Italy (sample
size: 4000 women). They underwent HPV test and
typing and are the object of the present report.
Previous knowledge on HPV epidemiology in Italy
Previously published Italian studies of circulating HPV
types in healthy women were affected by two main
problems: small sample size and limited extension of the
analysed geographical area. Most of them were performed
on samples from asymptomatic women who had sponta-
neously turned to gynaecologic clinics for cervical cancer
prevention or reproductive problems [6,7]. Only two studies
were based on a predetermined population sample. In these
cases, women were recruited from small geographical areas
[8,9] and one study was focused on young women only [9].
In southern Italy, the epidemiology of cervical cancer
is different compared to the rest of the country (table 1)
[10]. In particular, incidence is slightly lower than in the
centre and north. On the other hand, Pap test coverage
is higher in the north than in the south [11]. The com-
bination of these two data suggests differences in the
underlying HPV epidemiology.
Aim of the study
The aim of the present study was to measure the preva-
lence of different HPV types in the general population
attending population-based screening programmes in
Rome and southern Italy and to compare the data with
previously published Italian studies.
Methods
Setting
The study was conducted within cervical cancer
screening programmes that actively invite the entire tar-
get population (age ranging from 25 to 64) in Rome and
southern Italy. A convenience sample of the existing
screening programmes was selected: in Sicily and Sardi-
nia only two programmes issued invitations regularly
and were therefore selected, in Molise, Apulia and
Calabria there was no consolidated programme when
the study started and no data were collected from these
regions, in Abruzzo it was possible to collect samples
from the whole region, while in Rome metropolitan area
and Campania, the most populated areas, we selected
two programmes each.
In 2007, the target population for cervical cancer
screening, i.e. women aged 25-64, included 5.71 million
units in southern Italy and 1.18 million units in the
metropolitan area of Rome. The active screening pro-
grammes in these areas actually covered 4.75 million
women (69%) [12], while the target population of the
programs included in the sample was 1.50 million
women (22% of the total target population, 32% of the
population living in an area with an active screening
program).
Population and sample size
During the study period the programme invited the
target population, without any selection criteria (nor
age neither previous screening participation). We later
sampled about 800 women in each region (planned
sample size was 5 × 800, 4000). 25 to 65 year old
women were included in our study. Those repeating
Pap-test upon unsatisfactory or positive results, or as a
post-treatment and post-colposcopy follow-up, were
excluded.
Sample size (4000 women), was chosen in order to
achieve the two following objectives:
1. +/-3% precision in the estimate of the proportion
of infections of a type responsible for at least 10% of
infections;
Table 1 Cervical Cancer incidence, survival, Pap test coverage and Extension of Cervical cancer Programmes by
geographical area
North West North East Centre South and Island Italy
Incidence/100.000 2001-05 (AIRTum) [10] 7.1 7.3 6.2 7
Incidence/100.000 1996-2000 (AIRTum) [10] 8.5 7.5 7.4 8.1
Survival 2001-05 [10] 65% 68% 59% 65%
Pap test coverage (ISTAT 2004-05) [11] 79.5% 85.1% 78.1% 52.3% 70.9%
Cervical Cancer Screening Program implementation (GISCi) 2001 [12] 59.8% 68.8% 23.5% 40.1%
Cervical Cancer Screening Program implementation (GISCi) 2007 [12] 65.4% 91.9% 68.7% 71.8%
AIRTum: Associazione Italiana Registri Tumori; ISTAT: Istituto Nazionale di Statistica; GISCi: Gruppo Italiano Screening del Cervicocarcinoma
Giorgi Rossi et al. BMC Infectious Diseases 2010, 10:214
http://www.biomedcentral.com/1471-2334/10/214
Page 2 of 132. 95% power to see any type responsible for at least
1% of infections.
Considering overall HPV pr e v a l e n c et ob e1 0 % ,w e
expected 400 samples would be HPV positive and
therefore available for typing.
Sample collection
Cervical scrape samples were collected in ThinPrep vials
containing PreservCyt (Cytyc Corp., Marlborough, USA)
transport medium or in Specimens Transport Medium
(STM) (DNAPAP cervical sampler, Qiagen, Gaithers-
burg, USA). Before testing, 400 μl of STM samples,
vortexed on a shaking platform at 1000 rpm for at least
10 minutes, were biobanked at -80°C.
HPV testing
The presence of high risk (HR) and low risk (LR) HPVs
in cervical specimens was evaluated by Hybrid Capture
II® (HCII) (Qiagen, Gaithersburg, USA) [12-17] using
probemix B, specific for 13 HR HPV types: 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, and probemix
A, specific for 5 LR HPV types: 6, 11, 42, 43 and 44. To
lyse cells and release DNA, specimens collected in Pre-
servCyt® (no more than 20 samples at a time) were pro-
cessed with Digene Sample Conversion kit (Qiagen,
Gaithersburg, USA), according to the manufacturer’s
instructions. HCII assay followed. HPV DNA testing
was done locally in 3 sites (one in Abruzzo and two in
Rome) while samples collected in Cagliari and Catania
were analysed in Florence (ISPO). Results of HCII tests
for HPV DNA were expressed as relative light units
(RLU): specifically, the ratio of the specimen light emis-
sion to the average emission of three concurrently tested
positive controls (1 pg/ml HPV DNA). All samples with
a ratio value over 1 were considered HPV positive. HCII
quality assurance procedures were performed as pre-
viously described [18].
An additional internal control was then used in each
HCII test plate. At the beginning of the study, each labora-
tory denatured a quality control LR HPV sample (HPV
type 6 DNA) and a quality control HR HPV sample (HPV
type 16 DNA) provided with the kit. 100 μl of denaturated
control sample were aliquoted in 15 tubes and stored at
-20°C. Single aliquots were then used in every HCII plate.
Quality controls for both LR and HR HPV had a specific
concentration of virus DNA (5 pg/ml) and therefore an
expected ratio value ranging from 2 to 8.
For external quality assurance, 22 STM samples (100 μl)
were sent to one of the laboratories involved in the study
(Florence, ISPO) and samples had to be tested twice.
Laboratories that used PreservCyt® medium, sent 15 addi-
tional ThinPrep samples (4 ml) to the same facility, where
the whole HCII procedure was repeated.
Results were expressed as specimens in RLU/CO;
am o d a lv a l u e( i . e .t h em o s tf r e q u e n t l yp o s i t i v eo rn e g a -
tive value reported) was defined for each case in the
external control set and considered as the reference
result. The result provided from each single laboratory
was compared with the modal value.
Typing procedures
Typing procedures were centralized in Florence at the
ISPO laboratory and all the centres involved in the
study sent HR or LR HPV positive samples there.
For DNA extraction, 1.5 ml of samples in PreservCyt®
solution and 200 μl of STM samples were used to col-
lect DNA with a QIAamp DNAMini Kit. Samples were
eluted in 100 μl AE buffer preheated at 70°C. An HPV
negative sample was included in each batch of extrac-
tion to exclude any contamination during this phase.
HCII HR HPV positive specimens were amplified and
typed with “consensus High Risk HPV genotyping kit”
(Qiagen); this system uses PCR with biotinilated GP5+/
GP6+ primers, followed by reverse Line Blot for 18 high
risk HPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53,
56, 58, 59, 66, 68, 73 and 82.
PCR was performed in 50 μl final volume with 10 μl
DNA, 5 μl 10× buffer II, 7 μl2 5m MM g C l 2 ,1 0μl1
mM dNTPs, 0,3 μl AmpliTaqGold (Applied Biosystem)
DNA polymerase (5 U/μl) and 2 μlo fQ i a g e nP r i m e r
set, as recommended by the manufacturer. The thermal
cycler program contained ramping times between the
temperature used for denaturation, annealing and elon-
gation that appeared essential for optimal performance
[19]. Activation of the Taq polymerase (9 min at 94°C)
was followed by 40 PCR cycles: denaturation at 94°C for
20 seconds, with 2,8°C/sec ramp speed, annealing at
38°C for 30 seconds, with 1,8°C/sec ramp speed, and
elongation at 71°C for 80 seconds with 1,8°C/sec ramp
speed, and a final extension at 71°C for 4 minutes [19].
Amplified products were run on 2% agarose gels
containing ethidium bromide and visualized by ultravio-
let light.
All samples, independently from gel results, under-
went reverse line blot analysis. Biotinylated PCR pro-
ducts were hybridized with specific oligonucleotide
probes bound to membrane strips. After stringent wash-
ing, streptavidin-conjugated alkaline phosphatase was
added and a non-radioactive reaction performed using a
chromogenic substrate. Strips containing the resulting
purple precipitates were analysed visually from an inter-
pretation grid supplied with the kit. A biotinylated poly
(dT) control for conjugate reaction is present in each
strip to ensure good test performance and a proper
alignment of the strips on the interpretation sheet.
Samples were considered positive for a specific HPV
type if the precipitate was viewed in the specific position
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Page 3 of 13of the strip. In each run we included two negative con-
trols (a purified HPV negative DNA sample extracted in
the same batch as the test ones, and a DNA-free
sample) and two positive controls (HPV16 plasmid pur-
chased with the kit and a known non-16 HR HPV
DNA).
GP5+/6+PCR-negative and reverse Line Blot-negative
samples were amplified for the b-globin gene using pri-
mers GH20-PC04 (268 bp amplicon lenght) to assess
the integrity of DNA [20].
b-globin positive samples were re-typed with “INNO-
LiPA HPV genotyping Extra Amp” (Innogenetics,
Ghant, Belgium) following the manufacturer’si n s t r u c -
tions, because this system can detect 28 HPV HR or LR
types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 44, 45, 51,
52, 53, 54, 56, 58, 59, 66, 68, 69, 70, 71, 73, 74 and 82.
The b-globin negative samples were extracted and typed
again.
The remaining un-typed samples (GP5+/6+PCR-posi-
tive, reverse Line Blot-negative and INNO-LiPA nega-
tive) were considered HPV X type.
HCII LR HPV positive specimens (probe A specific for
5 LR types: 6,11,42,43,44) were typed using HPV 6 and
HPV 11 specific primers and resulting negative samples
were considered positive for the other LR types included
in probemix A (HPV 42,43,44). No LR type, other than
6 and 11, was searched for.
Primer sequences for HPV 6 were 5’-TAGTGGGCC-
TATGGCTCGTC-3’ (sense) and 5’-TCCATTAGCCTC-
CACGGGTG-3’ (antisense) which amplified a 289 bp
product.
Primer sequences for HPV 11 were 5’-GGAATA-
CATGCGCCATGTGG-3’ (sense) and 5’-CGAGCA-
GACGTCCGTCCTCG-3’ (antisense) which amplified a
360 bp fragment [21].
PCR reactions were performed in 25 μl reaction
volume using 5 μlD N A ,2 , 5μl 10× buffer II, 1,5 μl
25 mM MgCl2,2μl 2,5 mM dNTPs, 1,25 μl1 0μM pri-
mers, 0,2 μl Taq Gold (Applied Biosystems). Hot-start-
ing at 94°C for 6 min was followed by 40 cycles as
follows: 95°C for 30 sec, 58°C for 30 sec, 72°c for 30 sec
and an hold at 72°C for 5 min. Amplified products were
r u no n2 %a g a r o s eg e l sc o n t a i n i n ge t h i d i u mb r o m i d e
and visualized by ultraviolet light.
Systematic review
We searched the Medline using the terms ("HPV”
OR ("human” AND “Papillomavirus”)) AND ("type” OR
“Typing”) AND ("Italy” OR “Italian”) AND ("cervix” OR
“cervical”)A N D“prevalence”. The search was updated
on 15/12/2009. We excluded all studies that selected the
pathological population, women in follow-up or with a
positive Pap test. We included only studies reporting
prevalence in the general healthy population. We
extracted the total HPV positivity, the positivity to high
risk HPV, the proportion of HPV16 among isolated
HPV, the proportion of HPV 18 and the proportion of
cases with HPV16 or 18, the age of the population, the
geographical area.
Analysis
The following analyses were planned a priori in the
study design: prevalence of HPV positivity to high and
low risk probes by age, by centre; prevalence of HPV
16-18 by age, by centre; proportion of HPV types by
age, by centre. We calculated 95% confidence intervals
taking into account the two stages sample using STATA
8 survey module [22].
Ethics
The study has been approved by the Ethics Committee
of the Istituto Superiore di Sanità (the Italian National
Institute of Health, CE-ISS 07-162 e 07/163). Women
were informed of an additional HPV test in the screen-
ing procedure and asked to sign a consent form.
Results
Overall prevalence
In this study, 3817 women had one valid sample for
HPV testing, with both HR and LR probes. The overall
positivity was 9.2% (350/3817) (95% CI 6.2-12.2) for
high and 4.2% (160/3817) (95% CI 2.3-6.1) for low risk
types.
The prevalence of cytological modification was 3% of
ASCUS or more severe, in the centres using the Pap
test as primary screening.
Figure 1a shows the prevalence of HR and LR type
infection by age. Both are monotone decreasing curves,
but the slope is steeper for HR (slope -4.6 p < 0.00005)
than LR prevalence (slope -2.1 p < 0.00005). The two
slopes significantly differ (test for parallel slopes p <
0.00005), consequently the ratio between HR and LR
prevalent infections is 2, i.e. 17.1% (148/866) and 8.5%
(74/866), for 25-34 year old women and 1.4, i.e.2.9%
(15/517) and 2.1% (11/517), in 55-64 year old women.
The overall prevalence varies significantly by centre
(p < 0.00005 for HR and p < 0.00005 for LR types). The
observed variability is mostly due to a higher prevalence
of HR HPVs in Cagliari (Sardinia) and to a lower preva-
lence of LR types in Rome (Figure 1b).
T h ea g e - s p e c i f i cp r e v a l e n c ec u r v e sd on o ts h o w
heterogeneity except in Cagliari (Sardinia) that has a
steeper negative slope of the curve (test for parallel
slopes p < 0.00005) (Figure 1c).
The HCII quality control included co-testing of syn-
thetic samples with known HPV DNA concentration
and the circulation of clinical samples between labora-
tories to assess reproducibility, which was found to be
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Figure 1 Prevalence of HPV infection by type and age (a), type and centre (b), and age and centre, High Risk only (c).
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Page 5 of 13very high (kappa coefficient = 0.93 for positive vs.
negative).
Typing
Samples that showed high and/or low risk HPV with
HCII were 449: 293 among them displayed infection by
HR HPVs only, 99 by LR HPVs only, while 57 by both
HR and LR HPVs. In women younger than 25, we
detected 12 infections: 6 HR HPVs only, 4 LR HPVs
only and 2 HR and LR HPVs. These cases were
excluded from the analyses.
Out of 350 HR HPV positive samples, 300 (85.7%)
were immediately typed using the “Consensus High Risk
genotyping HPV” (Qiagen), 15 (4.3%) were typed with
INNO-LiPA “HPV Genotyping Extra Amp” (Innoge-
netics), 12 (3.4%) samples resulted PCR positive but
remained un-typed with rev e r s el i n eb l o tD i g e n ea n d
INNO-LiPA (10 HR only and 2 HR + LR) and the
remaining 23 (6.6%) beta-globin positive samples were
classified as HPV negative samples. Co-infections were
present in 97 HR positive women (27.7% among positive
samples, 2.5% of the general population).
Out of 160 LR HPV identified by probemix A HCII
(HPV 6, 11, 42, 43, 44), four samples were not available
for typing, 24 (15.4%) samples resulted HPV 6, 10 sam-
ples (6.4%) were positive for HPV 11 (4 of them were
HPV 6 and 11 co-infections) and 126 samples (80.7%)
were classified positive for other LR HPV types. No
other specific LR type was searched for.
The most common types were 16 (2.8%), 31 (1.1%), 51
(0.8%), 66 (0.7%) and 6 and 56 (0.6% both); HPV18
ranked tenth (0.5%) and HPV11 ranked sixteenth (0.3%).
Other low and undertermined risk types were found for
a total of 31 different types, some of these were not
included in the HCII probemixes. This fact is due to
cross-hybridization. Previous studies, in fact, suggested
that HCII using probemix B may cross-react with HPV
types either not associated or with undetermined asso-
ciations with cancer (non-oncogenic HPV) [23].
Table 2 shows HPV types by regional occurrence.
While HPV 16 is the most frequent type in all centres,
the second most frequent type is different in the various
centres: it is HPV 31 in Rome, Abruzzo and Campania
and it changes on the islands, HPV 6 in Sicily (p <
0.00005) and HPV 51 in Sardinia (p = 0.0025).
Table 3 shows the types by age. No evident trend can
be seen for any single virus type, but the prevalence of
HPV 16 is lower in 55-65 year old women, even if not
significantly.
Out of 97 women with HR HPV co-infections, 43
(44.3%) included HPV 16 and/or HPV 18. Table 4
shows the matrix of co-infections.
We have information on 17 histologically-confirmed
CIN2 or more severe lesions found among HPV positive
women. Including three co-infections, in these samples
we detected 21 types: the most frequent types were 16
(12 cases) followed by HPV types 31, 35, 66 (2 cases
each) and HPV types 33, 58, 73 (1 case each).
Systematic review
We found 72 papers in the PubMed search. Eleven of
them fulfilled the inclusion criteria, two more papers
were later excluded thorough analysis because preva-
lence data on HPV types were available only for a subset
of the healthy population selected according to Pap test
finding. Further literature was found in the IARC meta-
analysis: none of these papers were eligible because they
investigated only HR HPV prevalence and did not report
any typing.
Table 5 summarises results from the analysed studies.
The overall prevalence, in the same age classes, is lowest
in population-based studies [8,9], medium in opportu-
nistic screening studies [6,7] and highest in gynaecologi-
cal clinic-based studies [24,25,27,28,30,31]. The two
studies based on migrant population [26,29] showed the
highest overall prevalence and most widespread compo-
sition of types.
HPV 16 prevalence ranges from 2.8% to 9.6%; again
t h el o w e s tp r e v a l e n c ei sr e g i s t e r e di np o p u l a t i o n - b a s e d
studies. HPV 18 prevalence ranges from 0 to 6%.
Among included and excluded studies, only 4 were
large enough to give age-specific prevalence of HR-HPV.
Figure 2 reports prevalence by age.
Discussion
HR HPV prevalence
The overall prevalence observed in our study is lower
than what observed in most of the previous Italian stu-
dies even if we consider the same age classes (table 5).
All previous studies but two [8,9] were performed on a
population attending gynaecological clinics, including
opportunistic screening, or on high-risk populations. In
these studies, the observed prevalence of lesions is quite
high. Our study, in measuring HR HPV prevalence, has
an identical design and identical molecular methods of
the NTCC trial. Notably, results are extremely similar,
even if the centres included are not the same and the
geographical areas have social, cultural, economical and
historical differences. We will explore the implications
of this finding in the next paragraph. A more detailed
comparison is required from the recent study by Agar-
ossi and coll[28]. This study has a very large sample
with a quite low prevalence of ASCUS+ cytological
modification (6.4%). In our study, the prevalence of
cytological modification was 3%. Sampling women who
visit gynaecological clinics may select those who are
more sexually active than the average population.
Furthermore, having a previous abnormal Pap test
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Page 6 of 13Table 2 Distribution of HPV types by age and centres
Rome Campania Abruzzo Sicily Sardinia All
N% N%N% N%N%N %
All age 803 100.0 755 100 800 100.0 782 100 727 100 3867 100
<25* 1 0.1 31 4.1 0 0.0 5 0.6 9 1.2 46 1.2
25-34 144 17.9 173 22.9 181 22.6 130 16.6 238 32.7 866 22.4
35-44 258 32.1 241 31.9 255 31.9 295 37.7 245 33.7 1294 33.5
45-54 265 33.0 241 31.9 241 30.1 221 28.3 173 23.8 1141 29.5
55-64 134 16.7 67 8.9 123 15.4 130 16.6 62 8.5 516 13.3
65+* 1 0.1 2 0.3 0 0.0 1 0.1 0 0.0 4 0.1
25-64 years 801 722 800 776 718 3817
HR+ only 55 6.9 61 8.4 51 6.4 47 6.1 79 11.0 293 7.7
LR+ only 9 1.1 25 3.5 17 2.1 27 3.5 25 3.5 103 2.7
HR & LR+ 1 0.1 7 1.0 15 1.9 11 1.4 23 3.2 57 1.5
types
6 1 0.1 2 0.3 5 0.6 9 1.2 7 1.0 24 0.6
11 2 0.2 1 0.1 4 0.5 0 0.0 4 0.6 11 0.3
16 17 2.1 19 2.6 23 2.9 20 2.6 29 4.0 108 2.8
18 5 0.6 2 0.3 3 0.4 1 0.1 7 1.0 18 0.5
26 2 0.2 1 0.1 1 0.1 0 0.0 0 0.0 4 0.1
31 11 1.4 7 1.0 10 1.3 4 0.5 9 1.3 41 1.1
33 4 0.5 5 0.7 1 0.1 3 0.4 6 0.8 19 0.5
35 5 0.6 1 0.1 0 0.0 7 0.9 5 0.7 18 0.5
39 2 0.2 1 0.1 4 0.5 4 0.5 6 0.8 17 0.4
40 0 0.0 1 0.1 3 0.4 0 0.0 0 0.0 4 0.1
42 0 0.0 5 0.7 4 0.5 0 0.0 0 0.0 9 0.2
43 0 0.0 1 0.1 4 0.5 0 0.0 0 0.0 5 0.1
44 0 0.0 0 0.0 0 0.0 1 0.1 0 0.0 1 0.0
45 5 0.6 1 0.1 6 0.8 0 0.0 2 0.3 14 0.4
51 4 0.5 3 0.4 2 0.3 6 0.8 17 2.4 32 0.8
52 4 0.5 4 0.6 3 0.4 5 0.6 7 1.0 23 0.6
53 1 0.1 4 0.6 1 0.1 5 0.6 10 1.4 21 0.6
54 0 0.0 1 0.1 1 0.1 0 0.0 0 0.0 2 0.1
56 3 0.4 4 0.6 4 0.5 2 0.3 11 1.5 24 0.6
58 4 0.5 5 0.7 2 0.3 5 0.6 6 0.8 22 0.6
59 1 0.1 0 0.0 4 0.5 5 0.6 4 0.6 14 0.4
66 3 0.4 5 0.7 4 0.5 4 0.5 10 1.4 26 0.7
68 0 0.0 2 0.3 5 0.6 1 0.1 3 0.4 11 0.3
70 1 0.1 1 0.1 1 0.1 1 0.1 1 0.1 5 0.1
73 1 0.1 2 0.3 1 0.1 0 0.0 3 0.4 7 0.2
81 0 0.0 1 0.1 2 0.3 0 0.0 0 0.0 3 0.1
82 0 0.0 1 0.1 1 0.1 1 0.1 1 0.1 4 0.1
not typed
HR+ 0 0.0 22 3.0 2 0.3 4 0.5 6 0.8 34 0.9
LR+ 7 0.9 14 1.9 6 0.8 19 2.4 21 2.9 67 1.8
co-infections HR
2 9 1.1 11 1.5 15 1.9 19 2.4 26 3.6 80 2.1
3 3 0.4 5 0.7 0 0.0 1 0.1 6 0.8 15 0.4
4 1 0.1 0 0.0 0 0.0 0 0.0 1 0.1 2 0.1
*not included in the analyses
HR: High Risk; LR: Low Risk
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Page 7 of 13increases the probability of turning to the clinic for
further analyses, as noted by Agarossi and coll. [28]. On
the contrary, screening programmes included in our
study invite all the target population; furthermore, in
our programme all women not visiting the clinic for a
new first level round were excluded from the analyses.
Figure 2 compares the curves of HR HPV prevalence of
infection by age in the Italian studies published until
now: they show a similar decreasing curve of prevalence
at younger ages. Not surprisingly, studies based on orga-
nised screening programmes show a lower prevalence
than the study based on the population attending
gynaecological clinics [28], particularly at older ages.
HPV 16 prevalence has a similar variability than the
overall HPV prevalence, reflecting the same difference
due to the study-base. The variability in HPV 18
Table 3 Distribution of HPV positivity and types by age
<25* 25-34 35-44 45-54 55-64 All§
N% N % N% N% N % N%
All 46 100.0 866 100 1294 100 1141 100 516 100 3817 100
HR+ only 6 13.0 108 12.5 105 8.1 67 5.9 13 2.5 293 7.7
LR+ only 4 8.7 34 3.9 34 2.6 26 2.3 9 1.7 103 2.7
HR & LR+ 2 4.3 40 4.6 12 0.9 3 0.3 2 0.4 57 1.5
types
6 0 0.0 15 1.7 4 0.3 2 0.2 3 0.6 24 0.6
11 0 0.0 2 0.2 3 0.2 4 0.4 2 0.4 11 0.3
16 5 10.9 48 5.5 37 2.9 21 1.8 2 0.4 108 2.8
18 1 2.2 12 1.4 4 0.3 0 0.0 2 0.4 18 0.5
26 0 0.0 2 0.2 1 0.1 0 0.0 1 0.2 4 0.1
31 2 4.3 15 1.7 15 1.2 6 0.5 5 1.0 41 1.1
33 1 2.2 8 0.9 8 0.6 3 0.3 0 0.0 19 0.5
35 0 0.0 7 0.8 5 0.4 4 0.4 2 0.4 18 0.5
39 0 0.0 7 0.8 8 0.6 2 0.2 0 0.0 17 0.4
40 0 0.0 2 0.2 1 0.1 1 0.1 0 0.0 4 0.1
42 1 2.2 5 0.6 3 0.2 1 0.1 0 0.0 9 0.2
43 0 0.0 4 0.5 1 0.1 0 0.0 0 0.0 5 0.1
44 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0 1 0.0
45 0 0.0 3 0.3 4 0.3 6 0.5 1 0.2 14 0.4
51 2 4.3 15 1.7 10 0.8 6 0.5 1 0.2 32 0.8
52 0 0.0 11 1.3 8 0.6 4 0.4 0 0.0 23 0.6
53 0 0.0 11 1.3 5 0.4 4 0.4 1 0.2 21 0.6
54 0 0.0 0 0.0 0 0.0 1 0.1 1 0.2 2 0.1
56 0 0.0 10 1.2 7 0.5 7 0.6 0 0.0 24 0.6
58 0 0.0 8 0.9 10 0.8 3 0.3 1 0.2 22 0.6
59 0 0.0 6 0.7 7 0.5 3 0.3 0 0.0 16 0.4
66 1 2.2 11 1.3 12 0.9 1 0.1 0 0.0 24 0.6
68 0 0.0 5 0.6 4 0.3 2 0.2 0 0.0 11 0.3
70 1 2.2 1 0.1 2 0.2 2 0.2 0 0.0 5 0.1
73 0 0.0 6 0.7 0 0.0 1 0.1 0 0.0 7 0.2
81 0 0.0 0 0.0 1 0.1 1 0.1 1 0.2 3 0.1
82 0 0.0 1 0.1 1 0.1 2 0.2 0 0.0 4 0.1
not typed
HR+ 1 2.2 11 1.3 8 0.6 11 1.0 4 0.8 34 0.9
LR+ 2 4.3 21 2.4 23 1.8 17 1.5 6 1.2 67 1.8
co-infections
2 types 3 6.5 39 4.5 26 2.0 10 0.9 5 1.0 80 2.1
3 types 0 0.0 6 0.7 6 0.5 2 0.2 1 0.2 15 0.4
4 types 1 2.2 1 0.1 1 0.1 0 0.0 0 0.0 2 0.1
* these cases are excluded from analyses; four women over 65 were all negative for HPV
§ excluding <25 years.
HR: High Risk; LR: Low Risk
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Page 8 of 13prevalence is higher; this difference may reflect the
stronger influence of random fluctuations for this quite
rare type. Not surprisingly the two studies on migrant
population show a higher prevalence and a wider spec-
trum of types [26,29]. In fact, migrant women attending
gynaecological clinics are strongly selected to be at high
risk for sexually transmitted diseases.
In our study, we observed a strong variability among
centres in the circulating types, with the exception of
HPV 16. Most of the differences are due to Cagliari
(Sardinia). This area is relatively isolated, compared with
other Italian regions, as supported by observations on
genetic background [35].
LR HPV prevalence
The ratio between high and low risk infection types
decreases with age. This finding has been observed in
other studies [34]. There are several possible explana-
tions for this phenomenon and unfortunately a cross
sectional study cannot disentangle the question: 1) dif-
ferent types may circulate in different cohorts and there
m a yb el i t t l ee x c h a n g eb e t w e e nt h et w o ;2 )L Ra n dH R
types may elicit different immune responses and the
pool of immunised women for some of the more fre-
quent high risk viruses may increase in older cohorts,
consequently the prevalence of high risk infections
decreases more rapidly with age due to a more rapid
decrease in the susceptible population for high than low
risk viruses; 3) low risk infections, even while having vir-
tually no probability of progression, may also have lower
probability of clearance in the long term.
The relation between HPV prevalence and cervical cancer
incidence
The incidence of invasive cancer in Italy is slightly
lower in the South, 6.2/100.000, than in the North and
Centre, 7.1/100.000 and 7.3/100.000 respectively [10],
despite a much lower Pap test coverage in 2004-05,
according to the National Health Interview [11]: 83%,
78% and 52%, in the North, Centre, South respectively.
The two observations, i.e. a slightly lower incidence
and a much lower Pap test coverage in the south, had
been interpreted until now as indirect evidence that
HPV was less diffuse in this area and as indicative of
different sexual behaviours. Now we have studies
allowing for comparison of HPV prevalence in differ-
ent Italian areas: the overall prevalence observed in
our study in southern Italy is very similar to that
observed in the NTCC study in central and northern
Italy, even if slightly higher [5]. More precisely, preva-
lence is higher only in younger women, while in
women aged 55 or older it is slightly lower. This find-
ing is consistent with the study by Agarossi and coll.
[28] that did not find any geographical trend. In the
last decades, rapid changes in sexual behaviours
occurred in Italy, particularly in younger people. It is
Table 4 Matrix of co-infections in women positive to High Risk probe.
HPV type
HPV type 18 26 31 33 35 39 40 44 45 51 52 53 56 58 59 66 68 70 73
16 6236552 344422 5111
31 11 1 1 11 22
33 2 2 11 12
35 2 12
39 111 1 11
42 21 1
43 11
45 111
51 1 1311 1
52 1 1 111 1
53 1 1
54 11
56 11 2 1 1
58 111 11 1
66 11 2 1
70 11 1
81 1
82 1111
Triple infections are reported as three couples, quadruple infections as 12 couples. N 97
note:15 triple infection: 18/16/35 two; 16/66/33; 16/31/35; 31/73/42; 16/31/45; 16/33/51; 54/31/53; 51/52/56; 16/51/56; 16/53/58; 33/56/58; 35/59/66; 51/66/68; 16/52/70
2 quadruple infections 16/39/18/66; 16/26/31/39
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Page 10 of 13plausible that the cultural and behavioural changes
occurred earlier in northern than in southern Italy.
In our opinion, lower prevalence of HPV infection in the
previous decades is still the only plausible explanation for
lower incidence of invasive cancer in the South. In fact the
incidence currently observed by cancer registries is the con-
sequence of infections acquired several years ago. In this
scenario, the slightly higher prevalence of infection
observed now in southern compared to in northern Italy,
particularly in younger cohorts, may indicate that the South
is in transition from low to medium prevalence of HPV. As
a result, we may expect an increase in invasive cervical can-
cer incidence in the next decades if a better control by
screening programme is not implemented. This interpreta-
tion is coherent with the cervical cancer incidence trends
estimated by De Angelis and coll. [32], predicting differ-
ences between North and South would decrease.
Actually, the implementation of cervical cancer
screening in southern Italy is going on, even if with
great difficulties, and the effect on Pap test coverage in
some areas is now detectable [33].
Limits
We tested women who were invited and participated to
cervical cancer screening programmes in Rome and
southern Italy. Response to organised screening is quite
low, ranging from 25 to 50% in the selected areas; the
low participation may introduce a self-selection bias.
Nevertheless, active invitation was the only means we
had of reducing self-selection. Previous studies found
few socio-economic differences between participants
and not participants [36,37].
A second limit, due to the nesting of this study into
organised screening programmes, is that we could not
i n c l u d es o m er e g i o n s ,s u c h as Calabria and Apulia,
because at the time the study started there were no active
programmes that contacted the whole target population.
We decided not to gather information on the cytology
results in recruited women, since one centre used HPV
as the primary screening test. This choice limited the
opportunity of analyses.
We typed only women positive to the HR and LR
HCII probes; according to this protocol we may have
missed women who are positive to other HPV types not
included in the probes or samples with very low number
of virus DNA copies.
Conclusions
Pap-test coverage in southern Italy is lower than in
central and northern Italy. Nevertheless cancer regis-
tries until 2003 showed a similar or even lower cervical
cancer incidence in southern Italy than the rest of the
country. In this situation, a lower prevalence of HPV
infection in southern Italy was expected. Actually, the
observed HPV prevalence in the general female popu-
lation is slightly higher, in particular in younger
cohorts.
We interpret this finding as indicative of a transition
in southern Italy, from a low to medium-high preva-
lence area.
0
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25
30
<25 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 >=65
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Figure 2 High risk HPV prevalence of infection by age in the Italian studies published until now.
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Page 11 of 13The final effect of this transition may be an epidemic
of cancer in the next decades, if appropriate screening
programmes are not implemented to control the
disease.
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